摘要
目的:探讨活血消癥中药辨证治疗糖尿病肾病(Diabetic Nephropathy,DN)的有效性及安全性。方法:检索5个主要的电子数据库(中文数据库:中国知网(CNKI)、万方、维普(VIP),英文数据库:Medline、CENTRAL),检索日期从建库至2016年7月。筛选纳入并Meta分析活血消癥中药治疗DN的随机对照试验(Randomized Controlled Trials,RCT)。结果:活血消癥中药对于改善患者24 h尿蛋白定量(quantitative test of 24 h urinary protein,24 h UTP)(MD=-0.08 g,95%CI=[-0.13,-0.03],I^2=0%)和中医证候积分(MD=-3.82,95%CI=[-4.84,-2.79],I^2=0%)疗效优于ACEI/ARB类药物。对于SCr和BUN的影响,组间差异无统计学意义。结论:活血消癥中药降低DN患者24 h UTP和改善临床症状疗效优于ACEI/ARB类药物。
Objective：To explore the efficacy and safety of blood-activating and stasis-resolving herbs in treatment of diabetic nephropathy （DN）.Methods：A total of 5 major electronic databases were retrieved.Chinese databases include：CNKI,Wan Fang database,VIP database,English databases include：Medline,CENTRAL.Retrieve the date from inception date to July 2016.Meta-Analysis was used to analyze the randomized controlled trials （RCTs） in Chinese herbal medicine therapy for DN.Results：Blood-activating and stasis-resolving herbs is better than ACEI/ARB in improving 24 hUTP （MD =-0.08 g,95% CI =[-0.13,-0.03],I2 =0%） and TCM syndrome scores （MD =-3.82,95% CI =[-4.84,-2.79],I^2 =0%）.For the effects of SCr and BUN,there were no significant differences between the groups.Conclusion：Blood-activating and stasis-resolving herbs to reduce DN patients＇ 24 hUTP and improve clinical symptoms is better than ACEI/ARB.
出处
《世界中医药》
CAS
2017年第1期5-9,15,共6页
World Chinese Medicine
基金
北京市"十病十方"科技攻关项目
国家中医临床研究基地重点病种专项研究
关键词
活血消癥中药
糖尿病肾病
系统综述
META分析
Blood-activating and stasis-resolving herbs
Diabetic nephropathy
Systematic review
Meta-Analysis
